Search

everythinglearnresearchcommunity

for

Search:↓

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

E211 G>A gene linked to lower risk of severe prostate cancer and hair loss.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Physical activity, height, and smoking affect prostate cancer risk.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.

Certain natural compounds called terpenes may help prevent prostate cancer.

The document concludes that identifying the specific cells where skin cancers begin is important for creating better prevention, detection, and treatment methods.

KGF and its receptor are found in enlarged prostate tissue and KGF strongly increases cell growth.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

FDG PET/CT scans can change cancer treatment plans for dogs.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

ERG increases SOX9, promoting prostate cancer growth and invasion.

5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

Certain drugs that block specific enzymes can help treat prostate diseases.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Using finasteride with TIP extends time off period for prostate cancer patients.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

Ganoderma lucidum may help treat prostate cancer by blocking male hormones and slowing cancer cell growth.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.

A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.